Studie - Lupus Nephritis – Pipeline Review, H1 2012

Lupus Nephritis — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Lupus Nephritis - Pipeline Review, H1 2012', provides an overview of the Lupus Nephritis therapeutic pipeline. This report provides information on the therapeutic development for Lupus Nephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lupus Nephritis. 'Lupus Nephritis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Lupus Nephritis.
- A review of the Lupus Nephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lupus Nephritis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Lupus Nephritis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Lupus Nephritis Overview 8

Therapeutics Development 9

An Overview of Pipeline Products for Lupus Nephritis 9

Lupus Nephritis Therapeutics under Development by Companies 11

Lupus Nephritis Therapeutics under Investigation by Universities/Institutes 12

Late Stage Products 14

Comparative Analysis 14

Mid Clinical Stage Products 15

Comparative Analysis 15

Early Clinical Stage Products 16

Comparative Analysis 16

Discovery and Pre-Clinical Stage Products 17

Comparative Analysis 17

Lupus Nephritis Therapeutics — Products under Development by Companies 18

Lupus Nephritis Therapeutics — Products under Investigation by Universities/Institutes 19

Companies Involved in Lupus Nephritis Therapeutics Development 20

Bristol-Myers Squibb Company 20

Biogen Idec Inc. 21

Genentech, Inc. 22

Novartis AG 23

Teva Pharmaceutical Industries Limited 24

Deciphera Pharmaceuticals, LLC 25

NOXXON Pharma AG 26

NasVax Ltd. 27

Lupus Nephritis — Therapeutics Assessment 28

Assessment by Monotherapy Products 28

Assessment by Combination Products 29

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

Laquinimod - Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Anti-TWEAK - Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Orencia - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

NOX-A12 - Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

NOX-E36 - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Cyclosporine A - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Mycophenolate Mofetil + Prednisolone - Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Rituxan + Corticosteroids + Methylprednisolone + Mycophenolate mofetil - Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 46

Mycophenolate Sodium + Corticosteroids - Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Myfortic - Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Mesenchymal Stem Cell Transplantation - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Abatacept + Cyclophosphamide + Azathioprine + Prednisone - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 52

Mycophenolate Mofetil - Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Tamibarotene - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Advagraf - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Anti-aCD3 Mab - Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Cyclosporine + Mycophenolic Acid + Prednison - Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

DP-5599 - Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

cFMS Kinase Program - Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Lupus Nephritis Therapeutics — Drug Profile Updates 62

Lupus Nephritis Therapeutics — Discontinued Products 67

Lupus Nephritis Therapeutics - Dormant Products 68

Lupus Nephritis — Product Development Milestones 69

Featured News & Press Releases 69

Jun 03, 2010: CellCept Reached Positive Results In Phase III Trial In Lupus Nephritis 69

Jun 27, 2007: Preliminary Results For Phase III Study Evaluating CellCept In Lupus Nephritis. 69

Jan 26, 2007: Approval of Prograf for Lupus Nephritis in Japan 69

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 71

Disclaimer 71





List of Tables

Number of Products Under Development for Lupus Nephritis, H1 2012 9

Products under Development for Lupus Nephritis — Comparative Analysis, H1 2012 10

Number of Products under Development by Companies, H1 2012 11

Number of Products under Investigation by Universities/Institutes, H1 2012 13

Comparative Analysis by Late Stage Development, H1 2012 14

Comparative Analysis by Mid Clinical Stage Development, H1 2012 15

Comparative Analysis by Early Clinical Stage Development, H1 2012 16

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 17

Products under Development by Companies, H1 2012 18

Products under Investigation by Universities/Institutes, H1 2012 19

Bristol-Myers Squibb Company, H1 2012 20

Biogen Idec Inc., H1 2012 21

Genentech, Inc., H1 2012 22

Novartis AG, H1 2012 23

Teva Pharmaceutical Industries Limited, H1 2012 24

Deciphera Pharmaceuticals, LLC, H1 2012 25

NOXXON Pharma AG, H1 2012 26

NasVax Ltd., H1 2012 27

Assessment by Monotherapy Products, H1 2012 28

Assessment by Combination Products, H1 2012 29

Assessment by Stage and Route of Administration, H1 2012 31

Assessment by Stage and Molecule Type, H1 2012 33

Lupus Nephritis Therapeutics — Drug Profile Updates 62

Lupus Nephritis Therapeutics — Discontinued Products 67

Lupus Nephritis Therapeutics — Dormant Products 68





List of Figures

Number of Products under Development for Lupus Nephritis, H1 2012 9

Products under Development for Lupus Nephritis — Comparative Analysis, H1 2012 10

Products under Development by Companies, H1 2012 11

Products under Investigation by Universities/Institutes, H1 2012 12

Late Stage Products, H1 2012 14

Mid Clinical Stage Products, H1 2012 15

Early Clinical Stage Products, H1 2012 16

Discovery and Pre-Clinical Stage Products, H1 2012 17

Assessment by Monotherapy Products, H1 2012 28

Assessment by Combination Products, H1 2012 29

Assessment by Route of Administration, H1 2012 30

Assessment by Stage and Route of Administration, H1 2012 31

Assessment by Molecule Type, H1 2012 32

Assessment by Stage and Molecule Type, H1 2012 33

• Growth Hormone Deficiency – Pipeline Review, H1 2013
• Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H1 2013
• Growth Disorders – Pipeline Review, H1 2013
• Kidney Fibrosis – Pipeline Review, H1 2013
• Urinary Incontinence – Pipeline Review, H1 2013
• Global Endocrinology Drugs Market 2012-2016
• Inguinal Hernia Global Clinical Trials Review, H1, 2013
• End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline Review, H2 2012
• Microalbuminuria – Pipeline Review, H2 2012
• Nocturia – Pipeline Review, H2 2012
• Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012
• Hypoparathyroidism – Pipeline Review, H2 2012
• Proteinuria – Pipeline Review, H2 2012
• Thyroid Gland Disorders – Pipeline Review, H2 2012
• Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H2 2012
• Hypothyroidism Global Clinical Trials Review, H2, 2012
• Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2012
• Other Genito Urinary Disorders – Pipeline Review, H2 2012
• Urinary Retention Global Clinical Trials Review, H2, 2012
• Focal Segmental Glomerulosclerosis (FSGS) – Pipeline Review, H2 2012